ArticleTherapeutic advances in gastroenterology2024

Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study.

Sarah Fischer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.